BIPSE: A biomarker‐based phase I/II design for immunotherapy trials with progression‐free survival endpoint-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

BIPSE: A biomarker‐based phase I/II design for immunotherapy trials with progression‐free survival endpoint

Published:2021-11-25 Issue: Volume: Page:
ISSN:0277-6715
Container-title:Statistics in Medicine
language:en
Short-container-title:Statistics in Medicine

Author:

Guo Beibei¹^ORCID,Zang Yong²³^ORCID

Affiliation:

1. Department of Experimental Statistics Louisiana State University Baton Rouge Louisiana USA

2. Department of Biostatistics and Health Data Science Indiana University Indianapolis Indiana USA

3. Center for Computational Biology and Bioinformatics Indiana University Indianapolis Indiana USA

Funder

Foundation for the National Institutes of Health

Louisiana Board of Regents

Publisher

Wiley

Subject

Statistics and Probability,Epidemiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/sim.9265

Reference43 articles.

1. Cancer Immunotherapy

2. Cancer Immunotherapy Comes of Age

3. Cancer Immunotherapy and Breaking Immune Tolerance: New Approaches to an Old Challenge

4. A Bayesian Phase I/II Trial Design for Immunotherapy

5. SPIRIT: A seamless phase I/II randomized design for immunotherapy trials

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adaptive Bayesian information borrowing methods for finding and optimizing subgroup-specific doses;Clinical Trials;2024-01-19

2. Adaptive phase I–II clinical trial designs identifying optimal biological doses for targeted agents and immunotherapies;Clinical Trials;2024-01-11

3. Biomarker‐based precision dose finding for immunotherapy combined with radiotherapy;Biometrical Journal;2023-05-22

4. A Bayesian phase I/ II design to determine subgroup‐specific optimal dose for immunotherapy sequentially combined with radiotherapy;Pharmaceutical Statistics;2022-09-26

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3